Post-transplant malignancy: reducing the risk in kidney transplant recipients

Bibliography

• Wolfe RA, Ashby VB, Milford EL, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;12(23):1725-30
   Google Scholar
• Meier-Kriesche HU, Ojo AO, Port FK, Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001;12(6):1293-6
   PubMedGoogle Scholar
• Ojo AO, Port FK, Wolfe RA, Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994;24(1):59-64
   PubMedGoogle Scholar
• Oniscu GC, Brown H, Forsythe JL. How great is the survival advantage of transplantation over dialysis in elderly patients? Nephrol Dial Transplant 2004;19(4):945-51
   PubMedGoogle Scholar
• Johnson DW, Herzig K, Purdie D, A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000;69(5):794-9
   PubMedGoogle Scholar
• Jones DG, Taylor AM, Enkiri SA, Extent and severity of coronary disease and mortality in patients with end-stage renal failure evaluated for renal transplantation. Am J Transplant 2009;9(8):1846-52
   PubMedGoogle Scholar
• Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007;22(Suppl 1):i4-10
   Google Scholar
• U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. Available from: www.usrds.org [Last accessed 22 November 2010]
   Google Scholar
• Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994 – 2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI. Available from: http://optn.transplant.hrsa.gov/data [Last accessed 20 November 2010]
   Google Scholar
• Australia and New Zealand Dialysis and Transplant Registry, 2009. Available from: http://www.anzdata.org.au/v1/annual_reports_download.html [Last accessed 22 November 2010]
   Google Scholar
• van de Wetering J, Roodnat JI, Hemke AC, Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study. Transplantation 2010;90(12):1542-6
   PubMedGoogle Scholar
• Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355(9218):1886-7
   PubMedGoogle Scholar
• Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4(6):905-13
   PubMedGoogle Scholar
• Webster AC, Craig JC, Simpson JM, Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007;7(9):2140-51
   PubMedGoogle Scholar
• Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev 2010;6(9):511-19
   Google Scholar
• Buell JF, Beebe TM, Trofe J, Donor transmitted malignancies. Ann Transplant 2004;9(1):53-6
   PubMedGoogle Scholar
• Buell JF, Trofe J, Sethuraman G, Donors with central nervous system malignancies: are they truly safe? Transplantation 2003;76(2):340-3
   PubMedGoogle Scholar
• Buell JF, Gross T, Alloway RR, Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality. Transplant Proc 2005;37(2):583-4
   PubMedGoogle Scholar
• Feng S, Buell JF, Chari RS, Tumors and transplantation: the 2003 third annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003;3(12):1481-7
   PubMedGoogle Scholar
• Lipshutz GS, Baxter-Lowe LA, Nguyen T, Death from donor-transmitted malignancy despite emergency liver retransplantation. Liver Transpl 2003;9(10):1102-7
   PubMedGoogle Scholar
• National Cancer Institute SEER Cancer Statistics. Available from: http://www.cancer.org/Research/CancerFactsFigures/index [Last accessed 22 November 2010]
   Google Scholar
• Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999;68(12):1859-64
   PubMedGoogle Scholar
• Torbenson MS, Wang J, Nichols L, Occult nonhematopoietic malignancies present at autopsy in solid organ transplant patients who died within 100 days. Transplantation 2001;71(1):64-9
   PubMedGoogle Scholar
• Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2(4):14-17
   PubMedGoogle Scholar
• Yu H. Alcohol consumption and breast cancer risk. Jama 1998;280(13):1138-9
   PubMedGoogle Scholar
• Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3(9):565-74
   PubMedGoogle Scholar
• Rose RF, Moniem K, Seukeran DC, Compliance of renal transplant recipients with advice about sun protection measures: completing the audit cycle. Transplant Proc 2005;37(10):4320-2
   PubMedGoogle Scholar
• Ducloux D, Courivaud C, Bamoulid J, Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation 2008;85(12):1755-9
   PubMedGoogle Scholar
• Kasiske BL, Cangro CB, Hariharan S, The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001;1(Suppl 2):3-95
   PubMedGoogle Scholar
• Knoll G, Cockfield S, Blydt-Hansen T, Canadian society of transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005;173(10):1181-4
   PubMedGoogle Scholar
• Smith RA, Cokkinides V, Brooks D, Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60(2):99-119
   PubMedGoogle Scholar
• Doublet JD, Peraldi MN, Gattegno B, Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997;158(1):42-4
   PubMedGoogle Scholar
• Gulanikar AC, Daily PP, Kilambi NK, Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 1998;66(12):1669-72
   PubMedGoogle Scholar
• Chertow GM, Paltiel AD, Owen WF Jr, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 1996;156(12):1345-50
   PubMedGoogle Scholar
• Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2007;2(4):750-6
   PubMedGoogle Scholar
• Ozcay F, Arslan H, Bilezikci B, The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients. Transplant Proc 2009;41(7):2878-80
   PubMedGoogle Scholar
• Funch DP, Walker AM, Schneider G, Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5(12):2894-900
   PubMedGoogle Scholar
• Humar A, Hebert D, Davies HD, A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006;81(6):856-61
   PubMedGoogle Scholar
• Opelz G, Daniel V, Naujokat C, Dohler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009;88(8):962-7
   PubMedGoogle Scholar
• Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53(1):118-25
   PubMedGoogle Scholar
• Lim LY, Kowdley KV. Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine? Gastroenterology 2005;129(6):2120-2; discussion 2
   PubMedGoogle Scholar
• Saslow D, Castle PE, Cox JT, American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57(1):7-28
   PubMedGoogle Scholar
• Westman KW, Bygren PG, Olsson H, Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9(5):842-52
   PubMedGoogle Scholar
• Birkeland SA, Bendtzen K, Moller B, Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999;67(6):876-81
   PubMedGoogle Scholar
• Coomes SM, Wilke CA, Moore TA, Moore BB. Induction of TGF-beta 1, not regulatory T cells, impairs antiviral immunity in the lung following bone marrow transplant. J Immunol 2010;184(9):5130-40
   PubMedGoogle Scholar
• Maluccio M, Sharma V, Lagman M, Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003;76(3):597-602
   PubMedGoogle Scholar
• Harradine KA, Ridd K, Saunier EF, Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res 2009;15(16):5101-7
   PubMedGoogle Scholar
• McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 2009;101(6):1019-27
   PubMedGoogle Scholar
• Garnier JL, Blanc-Brunat N, Vivier G, Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas. Clin Transplant 1999;13(4):305-12
   PubMedGoogle Scholar
• Vajdic CM, McDonald SP, McCredie MR, Cancer incidence before and after kidney transplantation. Jama 2006;296(23):2823-31
   PubMedGoogle Scholar
• Mihalov ML, Gattuso P, Abraham K, Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10(3):248-55
   PubMedGoogle Scholar
• Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4(2):222-30
   PubMedGoogle Scholar
• Dantal J, Hourmant M, Cantarovich D, Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351(9103):623-8
   PubMedGoogle Scholar
• Kehinde EO, Petermann A, Morgan JD, Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994;81(7):985-6
   PubMedGoogle Scholar
• Urwin HR, Jones PW, Harden PN, Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 2009;87(11):1667-71
   PubMedGoogle Scholar
• van Leeuwen MT, Webster AC, McCredie MR, Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010;340:c570
   Web of Science ®Google Scholar
• Ben M'barek L, Mebazaa A, Euvrard S, 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007;215(2):130-3
   PubMedGoogle Scholar
• Piaserico S, Belloni Fortina A, Rigotti P, Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007;39(6):1847-50
   PubMedGoogle Scholar
• Ulrich C, Bichel J, Euvrard S, Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(Suppl 2):25-31
   PubMed Web of Science ®Google Scholar
• Campistol JM, Albanell J, Arns W, Use of proliferation signal inhibitors in the management of post-transplant malignancies–clinical guidance. Nephrol Dial Transplant 2007;22(Suppl 1):i36-41
   Google Scholar
• Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients–the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007;22(Suppl 1):i17-22
   PubMed Web of Science ®Google Scholar
• Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007;22(Suppl 1):i11-16
   Google Scholar
• Harwood CA, Attard NR, O'Donovan P, PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br J Cancer 2008;99(8):1276-84
   PubMedGoogle Scholar
• O'Donovan P, Perrett CM, Zhang X, Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309(5742):1871-4
   PubMedGoogle Scholar
• Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67(8):1167-98
   PubMedGoogle Scholar
• Kirk AD, Cherikh WS, Ring M, Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7(11):2619-25
   PubMed Web of Science ®Google Scholar
• Bustami RT, Ojo AO, Wolfe RA, Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4(1):87-93
   PubMedGoogle Scholar
• Snyder MJ, Stenzel TT, Buckley PJ, Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004;28(6):794-800
   PubMedGoogle Scholar
• Guba M, von Breitenbuch P, Steinbauer M, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-35
   PubMedGoogle Scholar
• Luan FL, Ding R, Sharma VK, Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63(3):917-26
   PubMedGoogle Scholar
• Luan FL, Hojo M, Maluccio M, Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73(10):1565-72
   PubMedGoogle Scholar
• Stallone G, Infante B, Pontrelli P, ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. Am J Transplant 2009;9(3):558-66
   PubMedGoogle Scholar
• Stallone G, Schena A, Infante B, Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23
   PubMedGoogle Scholar
• Kauffman HM, Cherikh WS, Cheng Y, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80(7):883-9
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87(2):233-42
   PubMed Web of Science ®Google Scholar
• Boratynska M, Banasik M, Patrzalek D, Klinger M. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes. Exp Clin Transplant 2008;6(1):59-66
   PubMedGoogle Scholar
• Durrbach A, Rostaing L, Tricot L, Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008;85(3):486-90
   PubMedGoogle Scholar
• Hsu HJ, Tian YC, Chen YC, The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery. Renal Fail 2008;30(3):303-6
   PubMedGoogle Scholar
• Barsoum RS, Morsey AA, Iskander IR, The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes. Exp Clin Transplant 2007;5(2):649-57
   PubMedGoogle Scholar
• Glotz D, Charpentier B, Abramovicz D, Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010;89(12):1511-17
   PubMedGoogle Scholar
• Barth RN, Janus CA, Lillesand CA, Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19(11):885-92
   PubMedGoogle Scholar
• Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int 2010;78:1068-74
   Google Scholar
• Campistol JM, Cockwell P, Diekmann F, Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 2009;22(7):681-7
   PubMedGoogle Scholar
• Furian L, Baldan N, Margani G, Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors. Clin Transplant 2007;21(1):57-62
   PubMedGoogle Scholar
• House AA, Nguan CY, Luke PP. Sirolimus use in recipients of expanded criteria donor kidneys. Drugs 2008;68(Suppl 1):41-9
   PubMedGoogle Scholar
• Diekmann F, Campistol JM, Saval N, Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation. Transplantation 2007;84(3):429-32
   PubMedGoogle Scholar
• Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22(1):1-15
   PubMedGoogle Scholar
• Carmellini M, Collini A, Ruggieri G, Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure. Transplant Proc 2008;40(6):1858-61
   PubMedGoogle Scholar
• Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77(5):760-2
   PubMed Web of Science ®Google Scholar
• Salgo R, Gossmann J, Schofer H, Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10(6):1385-93
   PubMed Web of Science ®Google Scholar
• Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 2009;36(Suppl 3):S46-58
   PubMedGoogle Scholar
• Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009;115(Suppl 10):2313-20
   PubMedGoogle Scholar
• Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009;115(16):3618-30
   PubMedGoogle Scholar
• Chinnakotla S, Davis GL, Vasani S, Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009;15(12):1834-42
   PubMedGoogle Scholar
• Saemann MD, Haidinger M, Hecking M, The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009;9(12):2655-61
   PubMedGoogle Scholar
• Augustine JJ, Chang PC, Knauss TC, Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006;81(7):1004-9
   PubMedGoogle Scholar
• Mendez R, Gonwa T, Yang HC, A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005;80(3):303-9
   PubMedGoogle Scholar
• Husain S, Raza K, Pilewski JM, Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009;87(12):1852-7
   PubMedGoogle Scholar
• Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008;86(2):192-9
   PubMedGoogle Scholar
• Heeger PS, Greenspan NS, Kuhlenschmidt S, Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999;163(4):2267-75
   PubMedGoogle Scholar
• Noris M, Casiraghi F, Todeschini M, Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007;18(3):1007-18
   PubMedGoogle Scholar
• Hricik DE, Rodriguez V, Riley J, Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003;3(7):878-84
   PubMedGoogle Scholar
• Nickel P, Presber F, Bold G, Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004;78(11):1640-6
   PubMedGoogle Scholar
• Visonneau S, Cesano A, Torosian MH, Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 1998;152(5):1299-311
   PubMedGoogle Scholar
• Stewart T, Tsai SC, Grayson H, Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346(8978):796-8
   PubMedGoogle Scholar
• Kiberd BA, Rose C, Gill JS. Cancer mortality in kidney transplantation. Am J Transplant 2009;9(8):1868-75
   PubMedGoogle Scholar
• Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002;62(5):1875-83
   PubMedGoogle Scholar